Showing posts with label biomedical. Show all posts
Showing posts with label biomedical. Show all posts

Thursday, November 17, 2011

Behavioral or Biomedical... Or both?!

via gaycitynews.com, by Perry N. Halkitis, Ph.D., M.S

"But is this radical shift from the behavioral to the biomedical the right course of action for all of us?
 
For me there are two bigger issues — one which I will fully address here, and the other to which I will allude."

Despite our best attempts over the last 30 years, the HIV epidemic continues unabated. There are 1.2 million identified infections in the United States, with another several hundred thousand likely undiagnosed. The impact of this ongoing health challenge is noted most dramatically and definitively evidenced among gay men, who represent somewhere in the vicinity of two to five percent of the population — but constitute 50 percent of all AIDS-related deaths, over 50 percent of all infections and over 50 percent of newly diagnosed infections.

With millions and millions of dollars spent on HIV prevention and research — and despite the best attempts of behavioral researchers and leading AIDS service organizations to modify our risk behaviors — the epidemic continues. Initial campaigns focusing on using a condom have, over time, morphed into programs underscoring the importance of efficacy, temptation and motivation to help shape behavior. But the infections continue to spread. So what has gone wrong?

Some, including myself at times, have pointed the finger at behavioral change programs that are overly simplistic, focusing on sex as an act free of emotion or passion (and in many cases, drugs). But sex is more than simple logic, or rational decision-making. Many behavioral programs have oversimplified a very complex behavior — and the programs we have developed or the research we have enacted has ultimately failed to translate to real lives. I often wonder if the folks developing these programs actually have sex themselves.
Some may argue that we have contained the disease. But how true is that when young gay men, especially Blacks and Latinos, are seroconverting at such high rates? Even among White men, there is an uptick in the incidence of new infections as this group navigates its 30s. We simply haven’t gotten it right.

Read the rest.


[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Wednesday, November 9, 2011

Microbicides 2012 Abstract and Scholarship Deadlines - November 17 (Aussie time)


Heads up IRMA, you have little more than a week to submit abstracts and apply for scholarships for the Microbicides 2012 conference scheduled for April 15 - 18, 2012 in Sydney, Australia.

Please take special note of the time - as Nov 17 in Australia could very well be Nov 16 where you are.

Here is the website: http://microbicides2012.org/

Here are key dates:

Abstract Submission

Thursday 17 November 2011 (Authors should submit abstracts no later than 5pm AEST time on Thursday 17 November 2011. TAKE NOTE OF THIS TIME and figure out what it means in your time zone - it will likely be much earlier, or even the day before.)

Scholarship Application

Thursday 17 November 2011 (Scholarship applications must be submitted online no later than 5:00 p.m Australian Eastern Standard Time - again, TAKE NOTE OF THIS TIME and figure out what that means in your time zone).
Successful applicants will be informed by e-mail after 16 January 2012.

Early Bird Registration
Tuesday 31 January 2012

Late Breaker Abstracts
Sunday 13 February 2012

Accommodation Booking
Friday 9 March 2012

Standard Registration
Thursday 15 March 2012

Conference Registration
Friday 30 March 2012

Conference
15 - 18 April 2012



[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Friday, September 24, 2010

NIH Releases Biennial Report of the Director

via NIH News Media Branch

Dr. Francis S. Collins, M.D., Ph.D, director of the National Institutes of Health, announced the release of the Biennial Report of the Director, NIH, for fiscal years 2008 and 2009. The report provides an integrated portrait of NIH research activities, making it easy for Congress, advocates and patient groups and the general public to understand the many activities of the agency. This is the second report under the mandate in the NIH Reform Act, which reinvented the NIH Biennial as a consolidated report, replacing many disparate ones. Now on NIH's website, the report will be available in print this fall.

The report contains an assessment of the state of biomedical and behavioral research organized by disease category, investigative approach, and resource. To ensure that the document reflects the work of all 27 institutes and centers, 16 trans-NIH teams gathered, reviewed, and organized information into a standardized format.

"When I began my tenure as NIH director a little more than one year ago, I restated our collective commitment to be as transparent as possible," said Dr. Collins. "We have worked to make the NIH Biennial Report a key resource for NIH's partners, collaborators and constituents — including members of Congress and their staff persons — to help keep them informed about what the agency is doing and why we are doing it."

Read more

Read the full report online

Thursday, July 29, 2010

Advancing the Science in a Time of Fiscal Constraint: Funding for HIV Prevention Technologies in 2009

Via AVAC
The report tracks the public, philanthropic and commercial investment in biomedical HIV prevention in 2009 including preventive and therapeutic HIV vaccines, microbicides, oral pre-exposure prophylaxis (PrEP), adult male circumcision, prevention of mother to child transmission, and HSV-2 suppression and prevention.


The report finds stability in funding for HIV prevention research from 2008 to 2009. HIV vaccines continued to receive the majority of funding, with a total of US$868 million, which was equal to 2008 funding levels. Investment in microbicides was US$236 million, a decline of 3 percent from 2008 levels. Funding for PrEP increased by 18 percent over 2008 levels to US$52 million.

The stability in funding is encouraging, given a 10 percent decrease in funding for AIDS vaccine research seen in 2008, but the Working Group identified several areas of concern if funding remains flat, including escalating costs of late-stage clinical research, dependency on a small group of funders and a lack of diversity in funders.

Recent and upcoming results from several major studies are already changing the trajectory of HIV prevention research and highlight the need for increased and sustained funding. This week's CAPRISA 004 results are tremendously exciting, but they are by no means the definitive answer about antiretroviral-based microbicides; appropriately resourced confirmatory and development research is urgently needed.

To download the full report, click here.

Saturday, July 24, 2010

AVAC Report 2010: Turning the Page

AVAC's 13th annual report, Turning the Page surveys, critiques and proposes recommendations for the field of biomedical prevention research: AIDS vaccines, microbicides and ARV-based prevention strategies such as PrEP and treatment as prevention.

As the report describes, scientific developments in several arenas of biomedical prevention research have re-energized the search for additional strategies. In the vaccine field this includes the first evidence of vaccine-induced protection and strides in identification of new potent, HIV-specific neutralizing antibodies. Antiretroviral-based prevention also shows potential, and the report provides context for the upcoming results of the CAPRISA 004 microbicide trial, the first effectiveness trial of an ARV-based prevention strategy in HIV-negative people.


For the full report click here.
Related Posts Plugin for WordPress, Blogger...